Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Devonian Health GroupTSXV:GSD 39 Market Cap is C$28.20 Mil as of Aug. 02, 2026. GuruFocus rates TSXV:GSD with a GF Score™ of 39/100. The stock has 7 warning signs investors should review. Among 1,423 Biotechnology companies, Devonian Health Group ranks worse than 75.33% on this metric.
Devonian Health Group's quarterly market cap
increased
from Oct. 2025 (C$28.21 Mil) to Jan. 2026 (C$31.81 Mil) and
increased
from Jan. 2026 (C$31.81 Mil) to Apr. 2026 (C$33.09 Mil).
Devonian Health Group's annual market cap
declined
from Jul. 2023 (C$39.73 Mil) to Jul. 2024 (C$27.42 Mil) and
declined
from Jul. 2024 (C$27.42 Mil) to Jul. 2025 (C$22.23 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Devonian Health Group's Enterprise Value for Today is C$27.62 Mil.
Devonian Health Group (TSXV:GSD) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSXV:GSD vs VRTX, REGN, RVMD: Market Cap Comparison
For the Biotechnology subindustry, Devonian Health Group's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Devonian Health Group Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Devonian Health Group's Market Cap distribution charts can be found below:
* The bar in red indicates where Devonian Health Group's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Devonian Health Group's Market Cap for the fiscal year that ended in Jul. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Devonian Health Group (TSXV:GSD) has a Market Cap of C$28.20 Mil as of Aug. 02, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Devonian Health Group and its competitors. According to the industry distribution chart, Devonian Health Group ranks #1072 out of 1423 companies in the Biotechnology industry, placing it in the top 75.3%.
Is Devonian Health Group's Market Cap too high?
Devonian Health Group's current Market Cap is C$28.20 Mil. Based on the distribution chart, Devonian Health Group ranks #1072 out of 1423 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Devonian Health Group has a GF Score™ of 39/100, reflecting its overall financial health beyond just this single metric.
How does Devonian Health Group's Market Cap compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Devonian Health Group ranks #1072 out of 1423 companies for Market Cap. This places Devonian Health Group in the lower half of its industry. The industry median Market Cap is 112.87. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 112.87, based on 1,423 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Devonian Health Group and its competitors. For the Biotechnology industry, the median Market Cap is 112.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Devonian Health Group's current Market Cap is C$28.20 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Devonian Health Group stock overvalued right now?
Devonian Health Group (TSXV:GSD) has a current Market Cap of C$28.20 Mil. The current Market Cap is C$28.20 Mil. Devonian Health Group's overall GF Score™ is 39/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Devonian Health Group (TSXV:GSD), the current Market Cap is C$28.20 Mil as of Aug. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Devonian Health Group Inc is operating in the pharmaceutical sector. It is engaged in the development and distribution of botanical drugs. The group is also involved in the development of value-added products for dermo-cosmetics. It has established a research effort focused on the anticipation of new solutions in the medical sector as well as in the cosmetic sector. The company's technology platform, The Supra Molecular Complex Extraction and Stabilization Technology provides a process of extraction, purification, stabilization, and conditioning of molecular complexes, as active botanical ingredients, from plants and algae. Its product portfolio includes pharmaceuticals like Thykamine, Pantoprazole, and Cleo-35; and cosmeceutical products like R-Spinasome and Purgenesis.
39GF Score
Get the complete analysis for TSXV:GSD
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSXV:GSD has been successfully added to your 
